- Research article
- Open Access
- Open Peer Review
Partner HIV serostatus disclosure and determinants of serodiscordance among prevention of mother to child transmission clients in Nigeria
© Onovo et al. 2015
- Received: 3 November 2014
- Accepted: 14 August 2015
- Published: 28 August 2015
Serodiscordance exists when the known HIV result of one member of a couple pair is positive while that of his/her partner is negative. In sub-Saharan Africa, in stable long-term couple partnerships (married or cohabiting), serodiscordance is a growing source of HIV-transmissions. This study aimed to ascertain across Nigeria, serodiscordance prevalence, partner HIV status disclosure and explore associations between suspected determinants and serodiscordance among PMTCT enrolled HIV positive pregnant women and their partners.
A retrospective Quality of Care performance evaluation was conducted in July 2013 among 544 HIV positive pregnant enrolees of PMTCT services in 62 comprehensive facilities across 5 of Nigeria’s 6 geo-political zones. Data of client-partner pairs were abstracted from pre-existing medical records and analysed using chi-square statistics and logistic regression.
A total of 544 (22 %) of 2499 clients with complete partner details were analysed. Clients’ age ranged from 15 to 50 years with a mean of 30 years. Serodiscordant prevalence was 52 % and chi-square test suggests no significant difference between serodiscordant and seroconcordant clients and their partners (p = 0.265). Serodiscordant rates were closely associated trend wise with national HIV sero-prevalence rates and the median CD4+ count was 425 ul/mm3 (IQR: 290–606 ul/mm3). Similar proportion of clients (99 %) received testing and agreed to disclose status to their partners. Yet, there was no association between clients agreement to disclose HIV status to their partners and these partners getting tested and receiving results (p = 0.919). Significantly, 87 % of clients in concordant HIV positive relationships appeared to be symptomatic (WHO clinical stage 3 or 4) compared to 13 % clients in HIV-discordant relationships (p < 0.003). Client’s age and CD4+ count did not aptly predict serodiscordance (Wald = 0.011 and 0.436 respectively). However, the WHO clinical staging appeared to be a better predictor of serodiscordance and concordance than other variables (Wald = 3.167).
The results suggest that clinical staging (WHO) could be a better predictor of client- partner pair discordant or concordant HIV serostatus. Early partner testing and notification can avert seroconversion, hence properly designed and mainstreamed interventions that target serodiscordant couples are essential.
- Serodiscordant Couple
- Serodiscordant Relationship
- Partner Disclosure
- Seroconcordant Relationship
- National Research Health Ethic Committee
Prevention of mother to child transmission (PMTCT) is vital for HIV/AIDS control [1–3]. In developing countries, antiretroviral (ARV) prophylaxis averted HIV infection in 409,000 children between 2009 to 2011 . However, PMTCT is not optimum in Nigeria, with largest number of new paediatric HIV infection globally occurring here – averaging 60 000 yearly from 2009 to 2012 . For enhanced PMTCT, mutual knowledge of partner’s HIV status is ideal , yet clinicians frequently have to presume that HIV-positive women have partners whose status are either negative or unknown.
We introduce the term ‘serodiscordancy’ to encompass serodiscordant and seroconcordant heterosexual couples. Serodiscordant or serodiscordance applies when one partner of an intimate couple pair’s HIV result is positive and other negative. If positive HIV results are known for both, this is a seroconcordant or seroconcordance relationship . A discordant status is particularly risky because regular coitus without condoms is more probable in stable long-term partnerships (married or cohabiting).
Serodiscordance is documented as a growing source of HIV-transmissions in sub-Saharan Africa (SSA) [8, 9], thus averting intra-couple transmission could amply impact the epidemic . Proper condom use  diminishes exposure and early ARV initiation lowers viral replication which limits transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples [12, 13].
Unprecedented antiretroviral therapy scale up has improved access for millions worldwide. In Nigeria, this means rapidly expanding numbers of People Living With HIV (PLWHIV) enrolled in treatment programs . For PLWHIV, evaluating the effectiveness of existing programs allows for development of context- specific strategies that addresses their sexual/reproductive aspirations, and attendant risks , including participation in a HIV serodiscordant relationship.
Furthermore, in stigma-rife parts of SSA, gender directed abuse may accompany disclosure of a HIV positive result [16, 17]. Though aberrant social-cultural and gender power constructs are plausible explanations, the availability of sexually transmitted infections (STIs) control services including pre-exposure prophylaxis must be considered
Several studies in Nigeria have examined serodiscordance and disclosure [18–20], but these were largely geographically-limited. From select PMTCT treatment facilities across Nigeria, this paper explores associations between certain predictors and serodiscordance among pregnant HIV-positive clients and their partners.
Nigeria is organized into six geo-political zones, which encompass neighbouring states (see Additional file 1). The study was conducted in 5 of the 6 geo-political zones excluding the North East zone due to security challenges. In July, 2013, locations providing comprehensive HIV/AIDS treatment services to pregnant women and their partners for at least one year were enrolled. Eventually, 62 ARV (known as comprehensive service delivery points) spanning primary, secondary and tertiary level facilities were eligible.
All pregnant women aged ≥ 15 years enrolled in PMTCT program in selected facilities in the study locations. Based on National PMTCT guidelines, pregnancy in the HIV positive woman is an indication for ARVs irrespective of CD4, VL or clinical stage .
A retrospective performance evaluation that measures Quality of Care (QoC) provided to HIV positive pregnant women and their exposed infants, particularly in the children’s first 2 years of life, in a 6-month review period (January 1st – June 30th, 2013).
HIV positive pregnant women identified in Antenatal Care (ANC) in 6 months prior to the beginning of the review period (July – December, 2012).
Unbooked HIV positive pregnant women who delivered at the facility in 6 months prior to the beginning of the review period (July – December, 2012).
All deliveries by HIV positive pregnant women (booked and unbooked) during 6 months of the review period (January 1st – June 30th, 2013).
HIV positive pregnant women who delivered in the facility 12 – 18 months prior to the beginning of the review period (July 2011 – December 2012).
Unbooked women are those who appear for the first time in the facility when in labour.
Sample frame was developed by applying the four inclusion criteria stated above to each audited patient’s medical folders. The sampling method varied from site to site, depending largely on the site’s information management system. For Electronic Medical Record enabled sites (which includes patient IDs, up-to-date clinical and other follow up information) all eligible sample of PMTCT patients was generated and audited. For paper-based medical record sites, a systematic random sampling was used to generate the required sample of PMTCT patients audited.
Determine the number of HIV+ pregnant women in each category (i – iv) in the 6 months reference period for each of categories i – iv (Xi - Xiv).
Determine PMTCT sample size for each of categories i - iv (Yi – Y iv) from the HIVQUAL sample size determination table (see Additional file 2).
Input the Y (Yi – Y iv) number of ANC IDs on the Random Number List(RNL).
Divide the total number of HIV+ pregnant women in each category (Xi - Xiv) by (Yi – Y iv) respectively. Approximate (X/Y) to the nearest whole number N.
Identify every Nth HIV+ woman’s ID, impute them serially into the RNL forms. Quality of PMTCT care will be reviewed for women with these IDs.
Where ‘’X” is the total sample of eligible population (Sample Frame) and ‘’Y” the sample size generated from HIVQual sample size determination table.
The QoC performance evaluation process involved use of care and treatment service delivery indicators and entries in national data collection tools (DCTs) to guide data abstraction from randomly selected pre-existing patients’ medical records. The four inclusion criteria stated in section 2.4 were applied to each audited medical folders.
For the PMTCT program component of the exercise, HIV negative pregnant women and HIV positive women with incomplete partner data were excluded from the sample of folders audited. Reliable and site specific data from the following registers - the Antenatal Care (ANC), HIV counselling and Testing, Delivery, Maternal, Partner, Early Infant Diagnosis, Child follow-up and ARV were reviewed and used to determine the pool of eligible sample of patients audited. The inclusion and exclusion criteria were applied on each step of the performance evaluation audit.
Data was sorted, coded, keyed into Microsoft Access database and exported to SPSS 20.0 for analysis. Results were presented using charts, graphs and frequency tables. Descriptive statistics such as mean, frequencies and percentages was used to describe and summarize findings. Contingency tables were developed, logistic regression and chi-square statistics tested associations between variables and level of significance (α = 0.05).
Ethical approval was obtained in line with the standard ethical procedures from the United States Centers for Disease Control and Prevention (CDC). The National Research Health Ethics Committee (NRHEC) of the Federal Ministry of Health Nigeria approved the primary survey. No clients were recruited for the PMTCT performance evaluation.
Study abstraction forms collated data from pre-existing client medical records and facility registers. Within facilities, abstraction was performed only in secure areas and data with or containing links to unique identifiers of study subject were kept under lock and key, until these records were appropriately returned to the facility records sections. All individuals involved in data abstraction and analysis received training on confidentiality procedures and obtained Collaborative Institutional Training Initiative (CITI) human subjects certification.
Proportion of total HIV clients by partners
Client’s with no partners
796.68 (p < 0.001)*
Client’s matched with partners
Approximately 78 % of clients with no available partner information (i.e., no partner HIV status documented in PMTCT partner register) were excluded. Poor documentation of partner HIV status in the PMTCT partner register at the study sites may have impacted on the results of the analysis as evident with the significant Chi-square goodness of fit χ2 (1) = 796.68, p = 0.001.
Proportion of serodiscordancy among HIV positive pregnant women and their sero-negative partners
Characteristics of geo-political regions
Proportion of serodiscordancy by geo-political zones
Proportion of clinical characteristics
Baseline CD4+ count
CD4 < 350
CD4 > 350
WHO clinical staging
In terms of WHO clinical staging, clients in seroconcordant relationships (87 %) appeared symptomatic (i.e., having a WHO clinical stage of 3 or 4) as compared to 52 % of the clients in serodiscordant relationships who were asymptomatic (i.e., having a WHO clinical staging of 1 or 2). The chi-square test suggest that there is a significant but weak association between clients being in seroconcordant or serodiscordant relationships with WHO clinical staging; χ2 (1) = 8,751, p < 0.003, Phi coefficient (φ) = −0.150.
Age demographic and clients HIV disclosure characteristics
Figure 6 shows the age disaggregated disclosure pattern of clients. As seen across all ages’ majority stated agreement to partner disclosure.
In terms of HIV testing and (HTC), less than two thirds (53 %) of the clients in serodiscordant relationships received HIV testing while 47 % of clients in seroconcordant relationships did not. 54 % of the clients in serodiscordant relationships agreed to disclose their HIV status to their partners, while 46 % of the clients in seroconcordant relationships reported otherwise.
The outcome of HIV testing and counselling (HTC) of PMTCT intervention in this study appeared a better fit among serodiscordant clients and their partners as compared to seroconcordant clients and their partners. The chi-square test of significance suggest no associations between these groups regarding HTC and clients agreement to disclosure of HIV status respectively; χ2 (1) = 0.012 and 0.024, p = 0.911 and 0.877.
Clients disclosure of HIV status characteristics
Proportion of partner disclosure among study clients
Agreed to partner disclosure
374.16 (p < 0.001)*
Did not agree to partner disclosure
Proportion of partner disclosure across the study regions
Agreed to partner disclosure
Did not agree to partner disclosure
Proportion of clients who agreed to disclosure of HIV status by their partners who received testing and counselling
Agreed to disclosure of HIV status
Did not agree to disclosure of HIV status
Partners tested and received results
Logistic regression model
−2 Log likelihood
Cox & Snell R Square
Nagelkerke R square
Hosmer and Lemeshow test
The cut value is .500b
Variables in the equation
95 % C.I.for EXP(B)
The disclosure process in the national HCT guidelines neither elicits partners’ age nor enforces enrolment/ARV status of HIV + partners  and weren’t available for analysis. The small sample size of the explanatory variable- WHO clinical stage (less than 15 for the WHO symptomatic category) could have affected the reliability of the Sig estimates, as it does not meet minimum statistical recommendations of at least 15 cases.
Data quality likely influenced findings, Nigeria’s health data management systems require urgent improvement. The retrospective methodology restricted research to use of historical data. Consequently, other important variables particularly partner’s age, ARV status/regimen, frequency and route of coitus were not available for analysis.
In conclusion, the regression model was a poor fit and indicates no significant association between the suspected determinants and serodiscordance. However, the WHO clinical staging appeared to be a better predictor of serodiscordancy than the other explanatory variables. For detailed explanation see logistic regression section above.
Effective disclosure begins at pre testing and runs through post counselling as explained in national guidelines. The algorithm contained is adequate on adhering to confidentiality and ensuring psychosocial support . Urgent attention is required to create, mainstream and harmonize male partner data in relation to pregnant women accessing PMTCT.
Likewise, research is essential on partners of HIV positive males (females in heterosexual partnerships and male partners of Men who have sex with Men-MSM). Associations with viral load, gestational age, nutrition, genetics and parity are other important indices or predictors and should be explored in subsequent studies.
Early partner testing and notification can avert seroconversion, thus expanding/redesigning interventions to accommodate serodiscordant couples is essential. Flexible policies on use of data generated by PEPFAR implementing partners (USAID/CDC) program for serodiscordant studies are helpful.
Serodiscordancy findings should be tracked in the national Mode of Transmission (MOT) reports across all the risk groups stated. Eventually, serodiscordant rates have methodological and statistical implications for relying on ANC HIV sero-prevalence as proxy for estimating national HIV prevalence.
The primary survey was the Nigeria Federal Ministry of Health (FMOH) nationwide HIV Quality of Care performance evaluation exercise delivered through its National Quality Improvement program. The CDC provides a grant for this. Authors were wholly responsible for the costs of the abstraction, communication, data collation, analysis and other associated costs.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Mnyani CN, McIntyre JA. Preventing mother-to-child transmission of HIV. BJOG. 2009;116 Suppl:71–6.View ArticleGoogle Scholar
- Ngemu EK, Khayeka-Wandabwa C, Kweka EJ, Choge JK, Anino E, Oyoo-Okoth E. Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women. BMC Res Notes. 2014;7:52.View ArticlePubMedPubMed CentralGoogle Scholar
- Nacius LA, Levison J, Minard CG, Fasser C, Davila JA. Serodiscordance and disclosure among HIV-positive pregnant women in the Southwestern United States. AIDS Patient Care STDS. 2013;27:242–7.View ArticlePubMedGoogle Scholar
- UNAIDS. World AIDS Day Report-Results. Geneva: UNAIDS; 2012.Google Scholar
- UNAIDS. Progress Report on the Global Plan: Towards the Elimination of New HIV Infections among Children by 2015 and Keeping Their Mothers Alive. Geneva: UNAIDS; 2013.Google Scholar
- Tadesse M. Assessment of HIV discordance and associated risk factors among couples receiving HIV test in Dilla, Ethiopia. BMC Res Notes. 2014;7:893.View ArticlePubMedPubMed CentralGoogle Scholar
- NACA. National Guidelines for HIV Counselling and Testing. Abuja: NACA; 2011.Google Scholar
- Matovu JKB. Preventing HIV transmission in married and cohabiting HIV-discordant couples in sub-Saharan Africa through combination prevention. Curr HIV Res. 2010;8:430–40.View ArticlePubMedGoogle Scholar
- Curran K, Baeten J, Coates T, Kurth A, Mugo N, Celum C. HIV-1 Prevention for HIV-1 Serodiscordant Couples. Curr HIV/AIDS Rep. 2012;9:160–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Bishop M, Karen F. Serodiscordant Couples in Sub-Saharan Africa: What Do Survey Data Tell Us? Washington, DC: Health Policy Initiative Order; 2010. p. 24.Google Scholar
- Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, Fideli U, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS. 2003;17:733–40.View ArticlePubMedGoogle Scholar
- Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.View ArticlePubMedPubMed CentralGoogle Scholar
- Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–404.View ArticlePubMedGoogle Scholar
- UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. Geneva: UNAIDS; 2012.Google Scholar
- Brubaker SG, Bukusi EA, Odoyo J, Achando J, Okumu A, Cohen CR. Pregnancy and HIV transmission among HIV-discordant couples in a clinical trial in Kisumu, Kenya. HIV Med. 2011;12:316–21.View ArticlePubMedGoogle Scholar
- Ezeanochie MC, Olagbuji BN, Ande AB, Kubeyinje WE, Okonofua FE. Prevalence and correlates of intimate partner violence against HIV-seropositive pregnant women in a Nigerian population. Acta Obstet Gynecol Scand. 2011;90:535–9.View ArticlePubMedGoogle Scholar
- Burgos-Soto J, Orne-Gliemann J, Encrenaz G, Patassi A, Woronowski A, Kariyiare B. Intimate partner sexual and physical violence among women in Togo, West Africa: Prevalence, associated factors, and the specific role of HIV infection. Glob Heal Action. 2014;7:23456.Google Scholar
- Sagay AS, Onakewhor J, Galadanci H, Emuveyan EE. HIV status of partners of HIV positive pregnant women in different regions of Nigeria: matters arising. Afr J Med Med Sci. 2006;35(Suppl):125–9.PubMedGoogle Scholar
- Olagbuji BN, Ezeanochie MC, Agholor KN, Olagbuji YW, Ande AB, Okonofua FE. Spousal disclosure of HIV serostatus among women attending antenatal care in urban Nigeria. J Obstet Gynaecol. 2011;31:486–8.View ArticlePubMedGoogle Scholar
- Sagay AS, Musa J, Ekwempu CC, Imade GE, Babalola A, Daniyan G, et al. Partner disclosure of HIV status among HIV positive mothers in Northern Nigeria. Afr J Med Med Sci. 2006;35(Suppl):119–23.PubMedGoogle Scholar
- Federal Ministry of Health. National Guidelines for Prevention of Mother-To-Child Transmission of HIV (PMTCT). Abuja: Federal Ministry of Health; 2010.Google Scholar
- Health Resources and Services Administration Bureau, New York State Department of Health AIDS Institute. HIVQUAL Workbook: Guide for Quality Improvement in HIV Care. New York: National HIV Quality Improvement (HIVQUAL) Project, New York State Department of Health AIDS Institute; 2006. p. 162.Google Scholar
- FMOH. National HIV Sero-Prevalence Sentinel Survey: Technical Report. Abuja: FMOH; 2010.Google Scholar
- De Bruyn G, Magaret A, Baeten JM, Lingappa JR, Ndase P, Celum C, et al. Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial. BMC Infect Dis. 2012;12:277.View ArticlePubMedPubMed CentralGoogle Scholar
- FMOH. HIV Counselling and Testing: A National HCT Trainee’s Manual. Abuja: FMOH; 2011.Google Scholar